Abstract |
We aimed to define the role of cyclophosphamide, vincristine, doxorubicin, prednisone (CHOP) followed by involved field radiotherapy (IFRT) for treating localized primary gastric diffuse large B-cell lymphoma (DLBCL). Newly diagnosed patients with localized primary gastric DLBCL were to receive four cycles of CHOP followed by IFRT of 40.0 Gy. At 1 year after the completion of treatment, patients filled out the EORTC Quality of Life Questionnaire specified for stomach cancer (QLQ-C30-STO22). Fifty evaluable patients (25 men, 25 women) were included. The median age was 54.5 years (range, 21 - 73 years. The overall response rate to the CHOP was 94% (95% confidence interval [CI], 87 - 100) in the intent-to-treat population. Forty-one of the 50 patients (82%; 95% CI, 71 - 93) achieved complete remission (CR). After the completion of radiotherapy, five patients who were in PR following chemotherapy eventually attained CR. The overall complete response rate was thus 92% (95% confidence interval, 84 - 99). With a median follow-up period of 30 months, the 2-year progression-free and overall survival rate was 92% and 92%, respectively. The gastric function was well preserved with negligible stomach-related symptoms at 1 year after the completion of treatment. This organ-preserving combined treatment is highly effective and well tolerated for the patients with localized gastric DLBCL.
|
Authors | Yeon Hee Park, Se-Hoon Lee, Won Seog Kim, Soo-Mee Bang, Baek-Yeol Ryoo, Sung Hyun Yang, Seung-Sook Lee, Mi Sook Kim, Kihyun Kim, Keon Woo Park, Do Hyoung Im, Jung Hun Kang, Jeeyun Lee, Young H Ko, Yong Chan Ahn, Do Hoon Lim, Keunchil Park |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 47
Issue 7
Pg. 1253-9
(Jul 2006)
ISSN: 1042-8194 [Print] United States |
PMID | 16923554
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Combined Modality Therapy
(methods)
- Cyclophosphamide
(administration & dosage)
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Lymphoma, B-Cell
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Prednisone
(administration & dosage)
- Quality of Life
- Remission Induction
- Stomach Neoplasms
(drug therapy, radiotherapy)
- Time Factors
- Vincristine
(administration & dosage)
|